Separately, Liberum Capital restated an under review rating on shares of Shield Therapeutics in a report on Monday, July 23rd.
Shield Therapeutics stock opened at GBX 30.50 ($0.40) on Thursday. Shield Therapeutics has a twelve month low of GBX 15 ($0.20) and a twelve month high of GBX 168.50 ($2.20).
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.
Featured Story: Treasury Bonds
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.